Korro Bio (KRRO.O) dosed first healthy volunteers in Phase 1/2 ANCHOR KRRO-121

Korro Bio dosed the first healthy-volunteer cohort in its Phase 1/2 ANCHOR trial of KRRO-121 for hyperammonemia; single 2 mg/kg dose, with interim readout expected in 2H 2027 and patient dosing expected in H1 2027.